Korea Research Institute of Bioscience and Biotechnology

St Pharm Co., Ltd.

Ho Kyung Chun

Young Ho Kim

Young Il Yeom

Hee Gu Lee

Kyung-Sook Chung

Eun Young Song

Seon-Young Kim

Jae Wha Kim

Chae-Ok Yun

Mi Sun Won

Moon Hee Kim

Young-Joo Kim

Kyeong-Eun Jung

Kyung Bin Song

Misun Won

Min Ah Kang

Shin-Jung Choi

Hyang Sin Lee

Sun-Jung Cho

Mi Young Park

In Seong Choe

Provided are a composition for diagnosing cancer or screening an anticancer drug comprising an FLJ25416 gene or an antibody directed to a protein expressed from the FLJ25416 gene, a composition for treating cancer comprising an inhibitor of the gene or an inhibitor of the protein expressed from the gene and a pharmaceutically acceptable carrier, and a kit for diagnosing cancer comprising at least one of the FLJ25416 gene and the protein expressed from the FLJ25416 gene. The FLJ25416 gene is expressed at high level in specific cancer cells, and induces an increase in proliferation rate of normal cells. The expression of the gene is suppressed, which results in an inhibitory effect on cancer cell growth. Thus, the FLJ25416 gene can be used as a target gene for diagnosis or treatment of cancer.

Use of FLJ25416 gene

Disclosed herein is a colorectal cancer marker for diagnosing colorectal cancer based on ESM-I overexpression in tissues, cells or body fluids of colorectal cancer patients. Disclosed also is the use of the colorectal cancer marker in the development of therapeutic agents for cancer and in the diagnosis and treatment of colorectal cancer.

Characterization of ESM-1 as a tumor associated marker of colorectal cancer

Growing community of inventors

Seoul, South Korea

Ho Kyung Chun